AtCor's pressure rises

By Dylan Bushell-Embling
Wednesday, 30 July, 2008

AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.

This represents a 47 per cent increase over last year's sales.

The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.

The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.

Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd